- Company
- Avastin’s Q1 sales drop sharply… future sales prospects?
- by May 25, 2022 05:47am
- Roche’s blockbuster anticancer drug ‘Avastin (bevacizumab) has recorded the lowest quarterly sales in 5 years. The drug had been much influenced by the drug price cut that followed the introduction of its biosimilars. However, whether the drop will continue remains to be seen due to the rise of new variables from the additional price cut a
- Company
- Yuhan Leclaza's first-quarter sales were 3.2 billion won
- by Chon, Seung-Hyun May 24, 2022 05:55am
- Yuhan's new anticancer drug Leclaza posted sales of 3 billion won in the first quarter. It has continued to rise since it entered the domestic market in earnest in the second half of last year. It is expected to surpass 10 billion won in annual sales for the first time among new anti-cancer drugs developed in Korea. According to IQVIA, on the
- Company
- Duodart may be prescribed at general hospitals in Korea
- by Eo, Yun-Ho May 24, 2022 05:55am
- The combination drug ‘Duodart’ that contains ‘dutasteride’ and ‘tamsulosin’ may be prescribed in general hospitals in Korea. According to industry sources, Duodart, GSK Korea’s fixed-dose combination drug for benign prostatic hyperplasia (BPH), has recently passed the drug committee (DC) review of Sinchon Severance Hospital and is
- Company
- Janssen makes first bid into lung cancer mkt with Rybrevant
- by May 24, 2022 05:55am
- “We will work to make Rybrevant, which had been first approved to treat EGFR exon 20 insertion mutations, the No.1 option for lung cancer patients in Korea.” Janssen Korea expressed so at the press conference that was held on the 23rd to celebrate the launch of Rybrevant in Korea. Rybrevant (amivantamab) received marketing authorization
- Company
- Alvogen, 1 in 3 failed patent attempts for Avastin
- by Kim, Jin-Gu May 24, 2022 05:55am
- Alvogen Korea failed to cross the last hurdle in the Roche anticancer drug Avastin patent challenge. It challenged three patents, but succeeded in overcoming only two and failed one. The Korean Intellectual Property Tribunal recently dismissed the Avastin patent invalidation trial filed by Alvogen Korea against Roche. As a result, the orig
- Company
- Ilaris reattempts reimb for its 13 patients in Korea
- by Eo, Yun-Ho May 23, 2022 06:06am
- ‘Ilaris,’ an ultra-orphan drug indicated for only 13 patients in Korea, is reattempting to be listed for insurance benefit. According to industry sources, Novartis Korea recently submitted an application to receive insurance benefits for its hereditary periodic fever syndrome treatment ‘Ilaris (canakinumab). This is the first attempt
- Company
- Keytruda became a new breakthrough in the tx
- by May 23, 2022 06:06am
- MSD's Keytruda succeeded in applying Hodgkin's lymphoma benefit for the second time as an immuno-cancer drug. Takeda is considered the best option for Hodgkin's lymphoma treatment. It is evaluated as suitable as a new option by proving superiority through comparative clinical trials with Takeda's Adcetris. As of March 1, Keytruda was reimburs
- Company
- Keytruda leads sales for the 9th consecutive quarter
- by Chon, Seung-Hyun May 23, 2022 06:06am
- MDS’s cancer immunotherapy Keytruda has again topped the rank in pharmaceutical sales this year. Its increase in sales has been reduced somewhat due to the price cut disposition that followed Keytruda's reimbursement expansion, still, the drug was able to maintain its lead for the 9th consecutive quarter. Also, new drugs from multinational phar
- Company
- The global competitiveness of new drugs depends on
- by Nho, Byung Chul May 23, 2022 06:06am
- Public opinion on the realization of the preference for new drugs developed in Korea is rising ahead of the announcement of the results of research services on drug prices support policies for innovative pharmaceutical companies in line with the international trade order. The research service, which took place for five months from December
- Company
- COVID-19 exports to Australia↑123 times in a year
- by Kim, Jin-Gu May 23, 2022 06:06am
- In the January-April period, exports of medicines to Australia surged more than 100 times compared to the same period last year-on-year. In the pharmaceutical bio industry, it is interpreted that the moderna vaccine produced by Samsung BioLogics was exported to Australia in earnest, leading to an increase in total exports. Exports to Germany,
